Skip to main content
letter
. 2023 Jun 22;108(12):3480–3484. doi: 10.3324/haematol.2022.282591

Figure 1.

Figure 1.

Pinworm exposure drives differences in leukemia/lymphoma development between Cdkn2a-/- and E6R1+ Cdkn2a-/- mice. (A) Timeline of individual survival studies following Cdkn2a-/- and E6R1+ Cdkn2a-/- mice in specific pathogen-free (SPF) and conventional facilities relative to the 2013 fenbendazole treatment. (B) Survival curves of leukemia/lymphoma development in Cdkn2a-/-(N=34) and E6R1+ Cdkn2a-/- (N=22) mice housed in an SPF facility during a pinworm outbreak prior to fenbendazole treatment. Arrows indicate the chronological order of the survival studies. The year in brackets corresponds to the date of euthanasia of the last mouse to develop illness in each cohort. (C, D) Survival curves from two independent experiments of mice housed in an SPF facility after pinworm was eradicated with fenbendazole treatment. 2016-2017: Cdkn2a-/- (N=58) and E6R1+ Cdkn2a-/- (N=40); 2017: Cdkn2a-/- (N=18) and E6R1+ Cdkn2a -/- (N=15). (E) Survival curve from one experiment in which Cdkn2a-/- (N=20) and E6R1+ Cdkn2a -/-(N=22) mice were housed in an SPF facility for 4 weeks, then transferred to a conventional facility for exposure to pinworm bedding. The log-rank (Mantel-Cox) test was applied to the survival curves.